Yuki Azuma

2 papers in the library · 1 citation · publishing 2025-2026

Papers

In vitro metabolic fate of 1-[3-(trimethylsilyl)propanoyl] lysergic acid diethylamide (1S-LSD), a silicon-containing LSD analog.

Forensic Toxicology July 29, 2025 Yuki Azuma, Misa Tanaka, Akiko Asada et al. 1 citation

A new LSD analog, 1S-LSD, which contains a silicon atom, was metabolized in human liver microsomes at a moderately rapid rate, forming LSD early in the process. Sixty-two metabolites were observed, and a metabolic pathway was proposed. The major metabolites had hydroxyl groups on the silicon-containing acyl moiety. Five metabolites that retained this moiety were relatively abundant: N-deethylated 1S-LSD (Si04), N-deethylated and silanolized 1S-LSD (Si06), N-deethylated and monohydroxylated 1S-LSD (Si09 and Si11), and silanolized 1S-LSD (Si21). These five are recommended as target markers for proving 1S-LSD consumption.

DOI: 10.1007/s11419-025-00735-2 Full text Lysergic acid diethylamide In vitro metabolism Metabolic pathway Silicon-containing drug +6

In Vitro Metabolism of 1‐Benzoyl‐Lysergic Acid Diethylamide (1Bz‐LSD) and Identification of a Deethylated Metabolite (1Bz‐LAE) Using a Synthesized Reference Standard

Drug Testing and Analysis February 17, 2026 Yuki Azuma, Akiko Asada, Misa Tanaka et al.

A newly emerged LSD analog, 1-benzoyl-LSD (1Bz-LSD), is rapidly metabolized in human liver microsomes, producing 15 metabolites including LSD itself. One deethylated metabolite remains detectable for a prolonged period, making it a promising target for confirming consumption. This metabolite was chemically synthesized and identified as 1-benzoyl-lysergic acid ethylamide (1Bz-LAE). The synthesis provides a crucial analytical foundation for investigating 1Bz-LSD use, with 1Bz-LAE expected to serve as a valuable marker for detection.

DOI: 10.1002/dta.70042 Lysergic acid diethylamide Metabolism Metabolic pathway Microsome +8